Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A+AVD versus ABVD as frontline therapy in advanced classical Hodgkin lymphoma
2011-005450-60Phase 3Active
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Nov 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Modified progression-free survival. Started Nov 2012; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2011-005450-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005450-60.